Shobhit Baijal, MBBS, MRCP, MRCP, The University Hospital Birmingham NHS Trust, Birmingham, UK, describes recent advances in targeted therapies for lung cancer. Whilst previous targets have primarily been EGFR, ALK, ROS1, there has been a recent increase in druggable mutations including NTRK, BRAF, RET, HER2, KRAS G12C, and MET exon 14 skipping mutations. Dr Baijal additionally highlights at use of novel targeted therapies in the adjuvant setting, following the approval of osimertinib based on the data from the Phase III ADAURA (NCT02511106) trial. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.